Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.

Georgios Kokolakis,Richard B Warren,Bruce Strober,Andrew Blauvelt,Luis Puig,Akimichi Morita,Melinda Gooderham, Andreas Körber,Veerle Vanvoorden,Maggie Wang,Dirk de Cuyper,Cynthia Madden,Natalie Nunez Gomez,Mark Lebwohl

The British journal of dermatology（2023）

引用 3|浏览27

暂无评分

摘要

High proportions of patients who did not adequately respond to adalimumab, ustekinumab or secukinumab achieved high levels of skin clearance after switching to bimekizumab. Bimekizumab was well tolerated and there were no new safety findings.

查看译文

关键词

bimekizumab efficacy,psoriasis,adalimumab,ustekinumab,moderate-to-severe

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要